297P - High-dose chemotherapy for inflammatory breast cancer: impact of immunohistochemical status on survival outcome

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Anticancer Agents
Breast Cancer
Biological Therapy
Presenter Laurys Boudin
Citation Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365
Authors L. Boudin1, C. Chabannon2, R. Sabatier3, F. Bertucci3, P. Sfumato4, C. Tarpin3, M. Provansal3, G. Houvenaegel5, E. Lambaudie5, A. Tallet6, R. Michel6, E. Charafe-Jauffret7, B. Calmels2, C. Lemarie2, B. Jean-Marie4, J. Extra3, P. Viens3, A. Gonçalves3
  • 1Oncologie Médicale, Hôpital d'Instruction des Armées (HIA) Ste Anne, 83000 - Toulon/FR
  • 2Centre De Therapie Cellulaire, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 3Oncologie Médicale, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 4Biostatistiques, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 5Chirurgie Oncologique, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 6Radiothérapie, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 7Biopathologie, Institute Paoli Calmettes, 13274 - Marseille/FR



Studies examining high-dose chemotherapy with autologous hematopoietic stem cell transplantation (HDC-AHSCT) strategies in inflammatory breast cancer (IBC), showed encouraging results in terms of disease-free survival (DFS), and overall survival (OS). The lack of data regarding HER2 status in all of these studies prevented any prognostic analysis involving breast cancer subtypes.


All consecutive female patients treated for IBC with HDC and AHSCT at Institut Paoli-Calmettes between 2003 and 2012 were included. Since 2005, trastuzumab was included in initial treatment. Patient, tumor and treatment characteristics were collected. Patients were categorized in three subtypes based on hormonal receptor (HR) and HER2 status of the primary tumor: Luminal, (HR + /HER2-), HER2 (HER2 + , any HR), and triple negative (TN) (HER2- and HR-). The main objective was the analysis of OS according to the IHC subtypes.


Sixty seven patients were included. Eleven patients received trastuzumab. Median follow up was 80.04 months (95% CI 73.2-88.08). Five-year OS and DFS for the whole population patients were 74% (95% CI 61-83) and 65 % (95% CI 52-75), respectively. OS differed across subtypes (p = 0.057) : HER2 subgroup appeared to have the best prognosis with a 5-year OS of 89% (95% CI 64-97) compared to 57% (95% CI 33-76) for the TN subgroup (HR 5.38, 95% CI 1.14-25.44; p = 0.034).


In IBC patients receiving HDC-AHSCT, OS favorably compares with data available in the literature on similar groups of patients. TN patients carried the least favourable OS and HER2 patients, half of them also receiving trastuzumab, had the best outcome. These findings provide additional information and options for patients with IBC and who could potentially benefit of HDC-AHSCT.

Clinical trial identification

Legal entity responsible for the study

Institut Paoli Calmettes


SIRIC program (INCa-DGOS-Inserm 6038).


All authors have declared no conflicts of interest.